234 related articles for article (PubMed ID: 23052165)
21. Perinodular ductular reaction/epithelial cell adhesion molecule loss in small hepatic nodules.
Zhang Q; Zhang CS; Xin Q; Ma Z; Liu GQ; Liu BB; Wang FM; Gao YT; Du Z
World J Gastroenterol; 2014 Aug; 20(31):10908-15. PubMed ID: 25152593
[TBL] [Abstract][Full Text] [Related]
22. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
[TBL] [Abstract][Full Text] [Related]
23. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
24. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.
Mosnier JF; Kandel C; Cazals-Hatem D; Bou-Hanna C; Gournay J; Jarry A; Laboisse CL
Mod Pathol; 2009 Feb; 22(2):182-90. PubMed ID: 18622386
[TBL] [Abstract][Full Text] [Related]
25. Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver.
Tsuneyama K; Kaizaki Y; Doden K; Kidani E; Harada K; Sasaki M; Nakanuma Y
Pathol Int; 2003 Feb; 53(2):90-7. PubMed ID: 12588436
[TBL] [Abstract][Full Text] [Related]
26. [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
Pozharisskiĭ KM; Granov DA; Ten VP; Kubaĭbergenova AG; Leenman EE; Rasskazov AI
Vopr Onkol; 2008; 54(4):417-33. PubMed ID: 18942395
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
30. Histopathology of hepatocellular carcinoma.
Schlageter M; Terracciano LM; D'Angelo S; Sorrentino P
World J Gastroenterol; 2014 Nov; 20(43):15955-64. PubMed ID: 25473149
[TBL] [Abstract][Full Text] [Related]
31. Glutamine synthetase, heat shock protein-70, and glypican-3 in intrahepatic cholangiocarcinoma and tumors metastatic to liver.
Lagana SM; Moreira RK; Remotti HE; Bao F
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):254-7. PubMed ID: 22914614
[TBL] [Abstract][Full Text] [Related]
32. [Combined hepatocellular-cholangiocarcinoma].
Jeen YM; Jin SY
Korean J Hepatol; 2007 Dec; 13(4):571-5. PubMed ID: 18159156
[No Abstract] [Full Text] [Related]
33. Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma".
Braxton DR; Saxe D; Damjanov N; Stashek K; Shroff S; Morrissette JD; Tondon R; Furth EE
Hum Pathol; 2017 Apr; 62():232-241. PubMed ID: 28232156
[TBL] [Abstract][Full Text] [Related]
34. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
36. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
37. Elevated expression of Bmi1 in hepatocellular carcinoma with bile duct tumor thrombi.
Zhang R; Xu LB; Zeng H; Yu XH; Wang J; Liu C
Hepatogastroenterology; 2013; 60(128):2042-7. PubMed ID: 24719948
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
39. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
Feng J; Zhu R; Chang C; Yu L; Cao F; Zhu G; Chen F; Xia H; Lv F; Zhang S; Sun L
PLoS One; 2016; 11(3):e0151501. PubMed ID: 26977595
[TBL] [Abstract][Full Text] [Related]
40. [Synchronous double primary hepatic cancer: hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Kim JO; Jun DW; Jang K
Korean J Gastroenterol; 2013 Aug; 62(2):135-9. PubMed ID: 24133714
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
